GSTC Stock Overview
A clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
GlobeStar Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0003 |
| 52 Week High | US$0.0025 |
| 52 Week Low | US$0.0002 |
| Beta | 1.61 |
| 11 Month Change | 0% |
| 3 Month Change | -50.00% |
| 1 Year Change | -81.25% |
| 33 Year Change | -97.69% |
| 5 Year Change | -91.18% |
| Change since IPO | -99.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| GSTC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.5% |
| 1Y | -81.3% | 15.6% | 30.7% |
Return vs Industry: GSTC underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: GSTC underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| GSTC volatility | |
|---|---|
| GSTC Average Weekly Movement | 34.9% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GSTC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GSTC's weekly volatility (35%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Jim Katzaroff | www.globestartherapeutics.com |
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021.
GlobeStar Therapeutics Corporation Fundamentals Summary
| GSTC fundamental statistics | |
|---|---|
| Market cap | US$372.33k |
| Earnings (TTM) | -US$919.30k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs GSTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSTC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$919.30k |
| Earnings | -US$919.30k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00074 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -20.2% |
How did GSTC perform over the long term?
See historical performance and comparison